Dr. Brown is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4460 Bissonnet
Ste 200
Bellaire, TX 77401Phone+1 713-524-3434Fax+1 713-524-3220
Education & Training
- University of Iowa Hospitals and ClinicsResidency, Ophthalmology, 1990 - 1995
- Baylor College of MedicineInternship, Transitional Year, 1988 - 1988
- Baylor College of MedicineClass of 1987
Certifications & Licensure
- TX State Medical License 1989 - 2025
- LA State Medical License 1996 - 2006
- IA State Medical License 1989 - 1997
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
- Fellow (FACS) American College of Surgeons
- Join now to see all
Clinical Trials
- Pilot Study of X-82 in Patients With Wet AMD Start of enrollment: 2012 Oct 01
- Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Start of enrollment: 2012 Oct 01
- A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema Start of enrollment: 2013 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 1031 citationsRanibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR StudyDavid M. Brown, Mark Michels, Peter K. Kaiser, Jeffrey S. Heier, Judy P. Sy
Ophthalmology. 2009-01-01 - 75 citationsSustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.Peter A Campochiaro, David M Brown, Carl C Awh, S Young Lee, Sarah Gray
Ophthalmology. 2011-10-01 - 70 citationsKESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.David M Brown, Andrés Emanuelli, Francesco Bandello, Jose Juan Escobar Barranco, João Figueira
American Journal of Ophthalmology. 2022-06-01
Press Mentions
- Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at the Retina Society Annual MeetingSeptember 15th, 2019
- Kodiak Sciences to Release Durability Data from Clinical Development Program of KSI-301 for Wet AMD at the Retina Society Annual MeetingSeptember 12th, 2019
- Effect of Initial Management with Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients with Diabetic Macular Edema Involving the Center of the Macula and Good Visual AcuityMay 1st, 2019
- Join now to see all
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: